Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CAN 3110

Next Previous
Search
Drug Profile

CAN 3110

Alternative Names: CAN-3110; rQNestin; rQNestin-34.5; rQnestin-34.5v.2

Latest Information Update: 10 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Brigham and Women's Hospital
  • Developer Candel Therapeutics; Dana-Farber Cancer Institute
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioma

Most Recent Events

  • 10 Mar 2025 CAN 3110 is still in phase I development in Glioma(Combination therapy, Recurrent, Second-line therapy or greater) in USA (Intratumoural, Injection) (NCT03152318)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Glioma(Combination therapy, Recurrent, Second-line therapy or greater) in USA (Intratumoural, Injection)
  • 05 Nov 2024 Pharmacodynamics and adverse events data from a preclinical trial in Glioma released by Candel Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top